[The evaluation of thrombolytic effect of snake venom antithrombus enzyme in treatment of acute myocardial infarction].
To evaluate the thrombolytic effect of Snake Venom Antithrombus Enzyme (SVATE) in the treatment of early acute myocardial infarction (AMI), 52 cases with AMI were randomly allocated to three groups, control (22 cases), SVATE (15 cases), and Urokinase (15 cases). The results show that SVATE can inhibit platelet aggregation, activate slightly fibrinolytic system and decrease markedly plasma fibrinogen level. However, the thrombolytic effect of SVATE in early treatment of AMI is not ideal, it can be used in combination with effective thrombolytic drugs to prevent reocclusion and reinfarction in AMI.
Zhang
S Y
SY
Department of Medicine, Peking Union Medical College Hospital, Beijing.
Jin
L
L
Yan
X W
XW
D000721:Ancrod / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D015912:Thrombolytic Therapy; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D000721:Ancrod; D014568:Urokinase-Type Plasminogen Activator